The use of biotechnological therapies for moderate‐to‐severe psoriasis is ever‐expanding and it is becoming increasingly more frequent to encounter different unforeseen events during their use, such as: fertile patients becoming pregnant and breast‐feeding, development of infections due to personal habits like tuberculosis, HBV, HCV or HIV, scheduling of surgical procedures, need of vaccinations, development of malignancy and evaluation of dose tapering. As any clinician may experience at least one of these unexpected events, it should be good practice to know how to manage them. Thus, a practical analysis has been proposed in this paper.

Palmoplantar psoriasis is difficult to treat and often recalcitrant to conventional therapies. Clinical trials have demonstrated the efficacy and safety of secukinumab for this debilitating psorias...

Article: Suicide risk and depression in patients with psoriasis - Italian Journal of Dermatology and Venereology 2022 December;157(6):497-501 - Minerva Medica - Journals